186 related articles for article (PubMed ID: 21779317)
1. DNA vaccines against dengue virus type 2 based on truncate envelope protein or its domain III.
Azevedo AS; Yamamura AM; Freire MS; Trindade GF; Bonaldo M; Galler R; Alves AM
PLoS One; 2011; 6(7):e20528. PubMed ID: 21779317
[TBL] [Abstract][Full Text] [Related]
2. T Cell Responses Induced by DNA Vaccines Based on the DENV2 E and NS1 Proteins in Mice: Importance in Protection and Immunodominant Epitope Identification.
Pinto PBA; Assis ML; Vallochi AL; Pacheco AR; Lima LM; Quaresma KRL; Pereira BAS; Costa SM; Alves AMB
Front Immunol; 2019; 10():1522. PubMed ID: 31333657
[TBL] [Abstract][Full Text] [Related]
3. Induction of a protective response in mice by the dengue virus NS3 protein using DNA vaccines.
Costa SM; Yorio AP; Gonçalves AJ; Vidale MM; Costa EC; Mohana-Borges R; Motta MA; Freire MS; Alves AM
PLoS One; 2011; 6(10):e25685. PubMed ID: 22031819
[TBL] [Abstract][Full Text] [Related]
4. Preliminary evaluation of DNA vaccine candidates encoding dengue-2 prM/E and NS1: their immunity and protective efficacy in mice.
Lu H; Xu XF; Gao N; Fan DY; Wang J; An J
Mol Immunol; 2013 Jun; 54(2):109-14. PubMed ID: 23270684
[TBL] [Abstract][Full Text] [Related]
5. The synergistic effect of combined immunization with a DNA vaccine and chimeric yellow fever/dengue virus leads to strong protection against dengue.
Azevedo AS; Gonçalves AJ; Archer M; Freire MS; Galler R; Alves AM
PLoS One; 2013; 8(3):e58357. PubMed ID: 23472186
[TBL] [Abstract][Full Text] [Related]
6. A DNA vaccine candidate expressing dengue-3 virus prM and E proteins elicits neutralizing antibodies and protects mice against lethal challenge.
De Paula SO; Lima DM; de Oliveira França RF; Gomes-Ruiz AC; da Fonseca BA
Arch Virol; 2008; 153(12):2215-23. PubMed ID: 19002647
[TBL] [Abstract][Full Text] [Related]
7. Dendritic Cell Targeting Using a DNA Vaccine Induces Specific Antibodies and CD4
Zaneti AB; Yamamoto MM; Sulczewski FB; Almeida BDS; Souza HFS; Ferreira NS; Maeda DLNF; Sales NS; Rosa DS; Ferreira LCS; Boscardin SB
Front Immunol; 2019; 10():59. PubMed ID: 30761131
[TBL] [Abstract][Full Text] [Related]
8. Combination of E- and NS1-Derived DNA Vaccines: The Immune Response and Protection Elicited in Mice against DENV2.
Pinto PBA; Barros TAC; Lima LM; Pacheco AR; Assis ML; Pereira BAS; Gonçalves AJS; Azevedo AS; Neves-Ferreira AGC; Costa SM; Alves AMB
Viruses; 2022 Jun; 14(7):. PubMed ID: 35891431
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein.
Raviprakash K; Kochel TJ; Ewing D; Simmons M; Phillips I; Hayes CG; Porter KR
Vaccine; 2000 May; 18(22):2426-34. PubMed ID: 10738100
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of chimeric DNA vaccines consisting of premembrane and envelope genes of Japanese encephalitis and dengue viruses as a strategy for reducing induction of dengue virus infection-enhancing antibody response.
Sjatha F; Kuwahara M; Sudiro TM; Kameoka M; Konishi E
Microbiol Immunol; 2014 Feb; 58(2):126-34. PubMed ID: 24372832
[TBL] [Abstract][Full Text] [Related]
11. Secretion of dengue virus envelope protein ectodomain from mammalian cells is dependent on domain II serotype and affects the immune response upon DNA vaccination.
Slon Campos JL; Poggianella M; Marchese S; Bestagno M; Burrone OR
J Gen Virol; 2015 Nov; 96(11):3265-3279. PubMed ID: 26358704
[TBL] [Abstract][Full Text] [Related]
12. Synergistic neutralizing antibody response to a dengue virus type 2 DNA vaccine by incorporation of lysosome-associated membrane protein sequences and use of plasmid expressing GM-CSF.
Raviprakash K; Marques E; Ewing D; Lu Y; Phillips I; Porter KR; Kochel TJ; August TJ; Hayes CG; Murphy GS
Virology; 2001 Nov; 290(1):74-82. PubMed ID: 11883007
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of a Candidate DNA Vaccine Based on the prM/E Genes of a Dengue Type 2 Virus Cosmopolitan Genotype Strain.
Putri DH; Sudiro TM; Yunita R; Jaya UA; Dewi BE; Sjatha F; Konishi E; Hotta H; Sudarmono P
Jpn J Infect Dis; 2015; 68(5):357-63. PubMed ID: 25766602
[TBL] [Abstract][Full Text] [Related]
14. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates.
Guirakhoo F; Weltzin R; Chambers TJ; Zhang ZX; Soike K; Ratterree M; Arroyo J; Georgakopoulos K; Catalan J; Monath TP
J Virol; 2000 Jun; 74(12):5477-85. PubMed ID: 10823852
[TBL] [Abstract][Full Text] [Related]
15. Dengue and Zika Virus Domain III-Flagellin Fusion and Glycan-Masking E Antigen for Prime-Boost Immunization.
Lin HH; Yang SP; Tsai MJ; Lin GC; Wu HC; Wu SC
Theranostics; 2019; 9(16):4811-4826. PubMed ID: 31367259
[TBL] [Abstract][Full Text] [Related]
16. Manipulation of immunodominant dengue virus E protein epitopes reduces potential antibody-dependent enhancement.
Hughes HR; Crill WD; Chang GJ
Virol J; 2012 Jun; 9():115. PubMed ID: 22709350
[TBL] [Abstract][Full Text] [Related]
17. DNA priming E and NS1 constructs--homologous proteins boosting immunization strategy to improve immune response against dengue in mice.
Mellado-Sánchez G; García-Cordero J; Luria-Pérez R; Lázaro-Olan L; Santos-Argumedo L; Gutiérrez-Castañeda B; Estrada-García I; Cedillo-Barrón L
Viral Immunol; 2005; 18(4):709-21. PubMed ID: 16359237
[TBL] [Abstract][Full Text] [Related]
18. A DNA vaccine candidate encoding the structural prM/E proteins elicits a strong immune response and protects mice against dengue-4 virus infection.
Lima DM; de Paula SO; França RF; Palma PV; Morais FR; Gomes-Ruiz AC; de Aquino MT; da Fonseca BA
Vaccine; 2011 Jan; 29(4):831-8. PubMed ID: 21115054
[TBL] [Abstract][Full Text] [Related]
19. The anamnestic neutralizing antibody response is critical for protection of mice from challenge following vaccination with a plasmid encoding the Japanese encephalitis virus premembrane and envelope genes.
Konishi E; Yamaoka M; Khin-Sane-Win ; Kurane I; Takada K; Mason PW
J Virol; 1999 Jul; 73(7):5527-34. PubMed ID: 10364301
[TBL] [Abstract][Full Text] [Related]
20. Tetravalent neutralizing antibody response against four dengue serotypes by a single chimeric dengue envelope antigen.
Apt D; Raviprakash K; Brinkman A; Semyonov A; Yang S; Skinner C; Diehl L; Lyons R; Porter K; Punnonen J
Vaccine; 2006 Jan; 24(3):335-44. PubMed ID: 16125280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
